JP7667778B2 - 呼吸器合胞体ウイルス(rsv)感染症を治療するためのベンゾジアゼピン誘導体 - Google Patents

呼吸器合胞体ウイルス(rsv)感染症を治療するためのベンゾジアゼピン誘導体 Download PDF

Info

Publication number
JP7667778B2
JP7667778B2 JP2022523558A JP2022523558A JP7667778B2 JP 7667778 B2 JP7667778 B2 JP 7667778B2 JP 2022523558 A JP2022523558 A JP 2022523558A JP 2022523558 A JP2022523558 A JP 2022523558A JP 7667778 B2 JP7667778 B2 JP 7667778B2
Authority
JP
Japan
Prior art keywords
pyrazole
phenyl
dihydro
oxo
carboxamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022523558A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022553700A (ja
JP2022553700A5 (cg-RX-API-DMAC7.html
Inventor
バレット、マシュー
スチュアート コッカリル、ジョージ
グッド、ジェームス
アレックス エイヴリィ、クレイグ
ジェームス コクラン、エドワード
Original Assignee
ファイザー・インク
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ファイザー・インク filed Critical ファイザー・インク
Publication of JP2022553700A publication Critical patent/JP2022553700A/ja
Publication of JP2022553700A5 publication Critical patent/JP2022553700A5/ja
Application granted granted Critical
Publication of JP7667778B2 publication Critical patent/JP7667778B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2022523558A 2019-10-22 2020-10-22 呼吸器合胞体ウイルス(rsv)感染症を治療するためのベンゾジアゼピン誘導体 Active JP7667778B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1915273.5 2019-10-22
GB201915273A GB201915273D0 (en) 2019-10-22 2019-10-22 Pharmaceutical compounds
PCT/GB2020/052658 WO2021079121A1 (en) 2019-10-22 2020-10-22 Benzodiazepine derivatives for treating a respiratory syncytial virus (rsv) infection

Publications (3)

Publication Number Publication Date
JP2022553700A JP2022553700A (ja) 2022-12-26
JP2022553700A5 JP2022553700A5 (cg-RX-API-DMAC7.html) 2023-10-23
JP7667778B2 true JP7667778B2 (ja) 2025-04-23

Family

ID=68728299

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022523558A Active JP7667778B2 (ja) 2019-10-22 2020-10-22 呼吸器合胞体ウイルス(rsv)感染症を治療するためのベンゾジアゼピン誘導体

Country Status (8)

Country Link
US (1) US20220409629A1 (cg-RX-API-DMAC7.html)
EP (1) EP4048665A1 (cg-RX-API-DMAC7.html)
JP (1) JP7667778B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220097420A (cg-RX-API-DMAC7.html)
CN (1) CN114761397B (cg-RX-API-DMAC7.html)
CA (1) CA3158169A1 (cg-RX-API-DMAC7.html)
GB (1) GB201915273D0 (cg-RX-API-DMAC7.html)
WO (1) WO2021079121A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201911944D0 (en) 2019-08-20 2019-10-02 Reviral Ltd Pharmaceutical compounds
GB201915932D0 (en) 2019-11-01 2019-12-18 Reviral Ltd Pharmaceutical compounds
GB202010409D0 (en) 2020-07-07 2020-08-19 Reviral Ltd Pharmaceutical compounds
WO2024252355A1 (en) 2023-06-08 2024-12-12 Pfizer Inc. Pediatric dosing regimens comprising a fusion inhibitor for the treatment of rsv
WO2025120500A1 (en) 2023-12-06 2025-06-12 Pfizer Inc. Benzodiazepine compounds as n-protein inhibitors
CN122580320A (zh) 2024-01-16 2026-08-14 辉瑞大药厂 作为n-蛋白抑制剂的苯二氮䓬吡唑甲酰胺类

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005090319A1 (en) 2004-03-19 2005-09-29 Arrow Therapeutics Limited Process for preparing benzodiazepines
JP2006503054A (ja) 2002-09-20 2006-01-26 アロー セラピューティクス リミテッド ベンゾジアゼピン誘導体およびそれらを含有する医薬組成物
JP2007529490A (ja) 2004-03-19 2007-10-25 アロー セラピューティクス リミテッド Rsv感染の処置または予防用ベンゾジアゼピン

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0221923D0 (en) * 2002-09-20 2002-10-30 Arrow Therapeutics Ltd Chemical compounds
GB0406282D0 (en) * 2004-03-19 2004-04-21 Arrow Therapeutics Ltd Therapeutic compounds
GB0406279D0 (en) * 2004-03-19 2004-04-21 Arrow Therapeutics Ltd Therapeutic compounds
CA2622592A1 (en) * 2005-09-19 2007-03-29 Arrow Therapeutics Limited Benzodiazepine derivatives for treating hepatitis c infection
US8871756B2 (en) * 2011-08-11 2014-10-28 Hoffmann-La Roche Inc. Compounds for the treatment and prophylaxis of Respiratory Syncytial Virus disease
GB201506448D0 (en) 2015-04-16 2015-06-03 Univ Durham An antimicrobial compound
MY197231A (en) * 2015-07-22 2023-06-06 Enanta Pharm Inc Benzodiazepine derivatives as rsv inhibitors
GB201613942D0 (en) 2016-08-15 2016-09-28 Univ Of Durham The An antimicrobial compound
WO2018129287A1 (en) 2017-01-06 2018-07-12 Enanta Pharmaceuticals, Inc. Heteroaryldiazepine derivatives as rsv inhibitors
WO2018226801A1 (en) 2017-06-07 2018-12-13 Enanta Pharmaceuticals, Inc. Aryldiazepine derivatives as rsv inhibitors
WO2020190935A1 (en) * 2019-03-18 2020-09-24 Enanta Pharmaceuticals, Inc. Benzodiazepine derivatives as rsv inhibitors
GB201911944D0 (en) * 2019-08-20 2019-10-02 Reviral Ltd Pharmaceutical compounds

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006503054A (ja) 2002-09-20 2006-01-26 アロー セラピューティクス リミテッド ベンゾジアゼピン誘導体およびそれらを含有する医薬組成物
WO2005090319A1 (en) 2004-03-19 2005-09-29 Arrow Therapeutics Limited Process for preparing benzodiazepines
JP2007529490A (ja) 2004-03-19 2007-10-25 アロー セラピューティクス リミテッド Rsv感染の処置または予防用ベンゾジアゼピン

Also Published As

Publication number Publication date
WO2021079121A1 (en) 2021-04-29
CN114761397B (zh) 2024-11-05
KR20220097420A (ko) 2022-07-07
US20220409629A1 (en) 2022-12-29
GB201915273D0 (en) 2019-12-04
CN114761397A (zh) 2022-07-15
CA3158169A1 (en) 2021-04-29
JP2022553700A (ja) 2022-12-26
EP4048665A1 (en) 2022-08-31

Similar Documents

Publication Publication Date Title
CN114761397B (zh) 用于治疗呼吸道合胞病毒(rsv)感染的苯并二氮䓬衍生物
JP7667779B2 (ja) 医薬化合物
CN107530329B (zh) 用作CDK抑制剂的吡唑并[1,5-a][1,3,5]三嗪和吡唑并[1,5-a]嘧啶衍生物
DK2978752T3 (en) 6- (5-HYDROXY-1H-PYRAZOL-1-YL) NICOTINAMIDE DERIVATIVES AND THEIR USE AS PHD INHIBITORS
KR101996335B1 (ko) 약제학적 화합물
TW202115065A (zh) Kras突變蛋白抑制劑
KR20250172881A (ko) 글루코스-의존성 인슐린 분비 촉진 폴리펩티드 수용체 길항제 및 이의 용도
JP7722981B2 (ja) 医薬化合物
TW201213332A (en) Pyrazolo[1,5-a]pyrimidines for antiviral treatment
JP2008545660A (ja) プロテインキナーゼ阻害剤として有用なピロロピリジン化合物
JP2011522865A (ja) Ia心不全および癌の治療に有用なプロテインキナーゼd阻害剤としての2,4’−ビピリジニル化合物
JP2023539986A (ja) 呼吸器合胞体ウイルス感染症の治療に有用なベンゾジアゼピン誘導体
CN111465600A (zh) 药物化合物
ES2905650T3 (es) Compuestos farmacéuticos
TW201607925A (zh) □啉化合物
WO2022180397A1 (en) Benzodiazepines for treating or preventing respiratory syncytial virus infection
CA2914541A1 (en) Novel aza-oxo-indoles for the treatment and prophylaxis of respiratory syncytial virus infection
RU2840815C2 (ru) Фармацевтические соединения
JP2026505488A (ja) サイトメガロウイルスの新規阻害剤
HK40039964B (en) Tricyclic compounds

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220607

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20220607

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20221213

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20230616

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230619

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231012

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231012

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240919

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241002

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241216

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250217

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250410

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250411

R150 Certificate of patent or registration of utility model

Ref document number: 7667778

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150